患者様やご家族など一般の方向け臨床・治癒情報サイト　臨床研究情報ポータルサイト

ENGLISH
国立保健医療科学院
クリップした情報
×

情報をクリップできます

治験情報をこちらのホームページで一時的にクリップすることが出来ます。

削除
治験例

海外の治験の状況「1」での検索結果

絞り込み

148件の検索結果
  • 進捗状況
  • 試験名
  • 対象疾患名
  • 地域
  • 登録日
  •  

  • Authorised

  • A Trial on Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors
  • Phase 1 – Part A dose escalation in patients with metastatic or locally advanced solid tumor for which no standard therapy exists or standard therapy has failed. Phase 2 - Part B unresectable or metastatic cervical cancer with disease progression after a platinum-based first-line regimen. MedDRA version: 20.0 Level: LLT Classification code 10008236 Term: Cervical cancer stage IV System Organ Class: 100000004864 MedDRA version: 20.0 Level: LLT Classification code 10008231 Term: Cervical cancer recurrent System Organ Class: 100000004864 MedDRA version: 20.0 Level: LLT Classification code 10065147 Term: Malignant solid tumor System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
  • Australia, Brazil, Hungary, Poland, Spain, Ukraine, United States
  • 2018-11-23

  • Authorised

  • A trial of AGEN1884 with AGEN2034 in Advanced Tumors
  • Phase 1 – Part A dose escalation in patients with metastatic or locally advanced solid tumor for which no standard therapy exists or standard therapy has failed. Phase 2 - Part B unresectable or metastatic cervical cancer with disease progression after a platinum-based first-line regimen. MedDRA version: 20.0 Level: LLT Classification code 10008236 Term: Cervical cancer stage IV System Organ Class: 100000004864 MedDRA version: 20.0 Level: LLT Classification code 10008231 Term: Cervical cancer recurrent System Organ Class: 100000004864 MedDRA version: 20.0 Level: LLT Classification code 10065147 Term: Malignant solid tumor System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
  • Australia, Brazil, Hungary, Poland, Spain, Ukraine, United States
  • 2018-09-26

  • Authorised

  • Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy alone for Patients With Lung Cancer (POSEIDON).
  • First-line patients with metastatistic non-small-cell lung cancer (NSCLC) with tumors that lack activating epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) fusions MedDRA version: 20.0 Level: LLT Classification code 10025055 Term: Lung cancer non-small cell stage IV System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
  • Brazil, Bulgaria, China, Germany, Hong Kong, Hungary, Japan, Korea, Republic of, Mexico, Peru, Poland, Russian Federation, South Africa, Taiwan, Thailand, Ukraine, United Kingdom, United States, Vietnam
  • 2017-05-29

  • Authorised

  • Research study investigating how well semaglutide works in people with type 2 diabetes suffering from overweight or obesity
  • 1. Obesity 2. Diabetes Mellitus, Type 2 MedDRA version: 20.0 Level: PT Classification code 10029883 Term: Obesity System Organ Class: 10027433 - Metabolism and nutrition disorders MedDRA version: 20.1 Level: LLT Classification code 10045242 Term: Type II diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disorders ;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
  • Algeria, Argentina, Canada, European Union, Greece, India, Japan, Russian Federation, South Africa, United Arab Emirates, United States
  • 2018-04-23

  • Authorised

  • Research study investigating how well semaglutide works in people with type 2 diabetes suffering from overweight or obesity
  • 1. Obesity 2. Diabetes Mellitus, Type 2 MedDRA version: 20.0 Level: PT Classification code 10029883 Term: Obesity System Organ Class: 10027433 - Metabolism and nutrition disorders MedDRA version: 20.1 Level: LLT Classification code 10045242 Term: Type II diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disorders ;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
  • Algeria, Argentina, Canada, European Union, Greece, India, Japan, Russian Federation, South Africa, Spain, United Arab Emirates, United States
  • 2018-03-07

  • Authorised

  • Multicenter Study of Oral Ozanimod as Maintenance Therapy in patients with Moderately to Severely Active Crohn’s Disease
  • Moderately to Severely Active Crohn’s Disease MedDRA version: 20.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
  • Argentina, Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, China, Croatia, Czech Republic, Denmark, Finland, France, Georgia, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic of, Latvia, Lithuania, Mexico, Moldova, Republic of, Netherlands, New Zealand, Norway, Poland, Portugal, Puerto Rico, Romania, Russian Federation, Saudi Arabia, Serbia, Singapore, Slovakia, Slovenia, South Africa, Spain, Sweden, Switzerland, Taiwan, Turkey, Ukraine, United Kingdom, United States
  • 2018-02-01

  • Authorised

  • Multicenter Extension Study of Oral Ozanimod in patients with Moderately to Severely Active Crohn’s Disease
  • Moderately to Severely Active Crohn’s Disease MedDRA version: 20.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
  • Argentina, Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, China, Croatia, Czech Republic, Denmark, Finland, France, Georgia, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic of, Latvia, Lithuania, Mexico, Moldova, Republic of, Netherlands, New Zealand, Norway, Poland, Portugal, Puerto Rico, Romania, Russian Federation, Saudi Arabia, Serbia, Singapore, Slovakia, Slovenia, South Africa, Spain, Sweden, Switzerland, Taiwan, Turkey, Ukraine, United Kingdom, United States
  • 2018-02-01